Gratifying results with combined Chemo-PRRT (177Lu-DOTATATE and platinum-based chemotherapy) in Recurrent Metastatic Sinonasal Neuroendocrine Carcinoma with high uptake on both 68Ga-DOTATATE and 18F-FDG PET-CT: a Promising Therapeutic Option.

: Sinonasal neuroendocrine carcinomas (SNC), in contrast to other sites, are notorious to be recurrent and locally aggressive. The clinical concern is primarily due to complex anatomy and close proximity to vital structures compounded by lack of proper understanding of pathogenesis, no definitive classification and staging system and established treatment guidelines. The promise of combined treatment with 177Lu-DOTA-(Tyr3)-octreotate (DOTATATE) based peptide receptor radionuclide therapy(PRRT) and with platinum-based chemotherapy in a patient of high grade recurrent and metastaticSNC (that demonstrated high uptake on both 68Ga-DOTATATE and 18F-FDG PET-CT), with significant partial response is presented. The study report highlights the feasibility and effectiveness of combined Chemo-PRRT protocol in management of SNC demonstratingpromising results in high grade recurrent metastatic SNC.